...of two NCEs from the stigmine platform. The stigmine platform was acquired in 2005 from Sention Inc....

...Infectious Hired: David Mantus as VP of regulatory affairs, formerly VP of regulatory affairs at Sention Inc. WIR...

...and wts 4/30/03 $46.0 Nick Simon Rinat Neurology U.S. Series B 8/19/03 $40.0 Dennis Henner Sention...

...MRK granted Sention exclusive rights to a family of preclinical mGluR5 receptor antagonists for Down Syndrome...
...compounds for Huntington's disease. Sention is developing candidates for cognitive impairment and other CNS disorders. Sention Inc....

...MRK granted Sention (Providence, R.I.) exclusive rights to a family of preclinical mGluR5 receptor antagonists for...
...retardation. The neurology company also received an option to license the compounds for Huntington's disease. Sention...

...Pharmaceuticals Inc. (South San Francisco, Calif.), formulation play TransForm Pharmaceuticals Inc. (Lexington, Mass.), memory company Sention Inc....

...Partners; Arch Venture Partners; Montreux Equity Partners; CalPERS; TIAA; Duke University; University of North Carolina Sention...

...Sention raised $13 million in a private financing through MPM Capital and Burrill & Co. Sention...